CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 7 enrolled
Drug / intervention
Escitalopramdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00833469
NCT00833469Phase 4Completed
CompareCT.gov

Escitalopram for the Treatment of Postpartum Depression

Massachusetts General Hospital·interventional·Posted Feb 2, 2009·Updated Aug 6, 2014

In Brief

A Phase 4 clinical trial evaluating Escitalopram for Postpartum Depression. Completed, enrolled 7 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether women with postpartum major depressive disorder (MDD) will experience a significant decrease in depressive symptoms from baseline over an eight-week treatment intervention with escitalopram (Lexapro). Also, to determine whether women with postpartum MDD will experience a significant decrease in anxiety symptoms.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostpartum Depression
CountriesUnited States
CollaboratorsForest Laboratories

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2, 2009
Enrollment StartJan 1, 2009
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 17.4 years ago

Interventions

Escitalopramdrug

Once daily by mouth